New treatment options for the management of restless leg syndrome

Journal of Neuroscience Nursing

Volumn 46, Issue 4, 2014, Pages 227-232

  Toro, Beatriz Elizabeth Carmona ^a  

^a Neurology Service of Orlando   (United States)

Author keywords

Augmentation; Gabapentin enacarbil; Horizant; Neupro; Restless leg syndrome; RLS; Rotigotine

Indexed keywords

1-(((ALPHA-ISOBUTANOYLOXYETHOXY)CARBONYL)AMINOMETHYL)-1-CYCLOHEXANEACETIC ACID; 4 AMINOBUTYRIC ACID; CARBAMIC ACID DERIVATIVE; ROTIGOTINE; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; CONTROLLED CLINICAL TRIAL (TOPIC); CUTANEOUS DRUG ADMINISTRATION; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; MIDDLE AGED; NURSING; NURSING DIAGNOSIS; PREGNANCY; PROTOCOL COMPLIANCE; RESTLESS LEGS SYNDROME; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; CARBAMATES; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMMA-AMINOBUTYRIC ACID; GUIDELINE ADHERENCE; HUMANS; MIDDLE AGED; NURSING DIAGNOSIS; PREGNANCY; RESTLESS LEGS SYNDROME; TETRAHYDRONAPHTHALENES; THIOPHENES; YOUNG ADULT;

EID: 84905816975     PISSN: 08880395     EISSN: 19452810     Source Type: Journal    
DOI: 10.1097/JNN.0000000000000068     Document Type: Article

References (29)

1. Allen, R. P., & Earley, C. J. (1996). Augmentation of the restless legs syndrome with carbidopa/levadopa. Sleep, 19(3), 205-213.
2. Allen,R. P., Ondo,W.G., Ball, E., Calloway, M. O., Manjunath, R., Higbie, R. L., ⋯ Nisbet, P. A. (2011). Restless legs syndrome (RLS) augmentation associated with dopamine agonists and levadopa usage in a community sample. Sleep Medicine, 12(5), 431-439.
3. Byrne, R., Sinha, S., & Chaudhuri, K. R. (2006). Restless legs syndrome: Diagnosis and review of management options. Neuropsychiatric Disease and Treatment, 2(2), 155-164.
4. Cundy, K., Sastry, S., Luo, W., Zou, J., Moors, T., & Canafax, D. (2008). Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. Journal of Clinical Pharmacology, 48, 1378-1388.
5. Dhawan, V., Ali, M., & Chaudhuri, K. R. (2006). Genetic aspects of restless legs syndrome. Postgraduate Medical Journal, 82, 626-629.
6. Douglas, N. (2002). Clinicians' guide to sleep medicine. NewYork, NY: Arnold.
7. Ellenbogen, A., Thein, S., Winslow, D., Becker, P., Tolson, J., Lassauzet, M., & Chen, D. (2011). A 52-week study of gabapentin enacarbil in restless legs syndrome. Clinical Neuropharmacology, 34(1), 8-16.
8. Garcia-Borreguero, D., Allen, R. P., Kohnen, R., Högl, B., Trenkwalder, C., Oertel, W., ⋯ Earley, C. J.; International Restless Legs Syndrome Study Group. (2007). Diagnostic standards for dopaminergic augmentation of restless legs syndrome: Report from a World Association of Sleep Medicine International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Medicine, 8(5), 520-530.
9. Garcia-Borreguero, D., Högl, B., Ferini-Strambi, L., Hill-Zabala, C., Asgharian, A., & Allen, R. (2012). Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): Results from a prospective multicenter study over 66 weeks. Movement Disorders, 27(2), 277-283.
10. Hening, W. A., Allen, R. P., Ondo, W. G., Walters, A. S., Winkelman, J. W., Becker, P., ⋯ Schollmayer, E.; SP792 Study Group. (2010). Rotigotine improves restless legs syndrome: A 6-month randomized, double blind, placebocontrolled trial in the United States. Movement Disorders, 15(25), 1675-1683.
11. Högl, B., Garcia-Borreguero, D., Trenkwalder, C., Ferini-Strambi, L., Hening, W., Poewe, W.,⋯ Allen, R. P. (2011). Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Medicine, 12(4), 351-360.
12. International Restless Legs Syndrome Study Group. (2013). Diagnostic criteria. Retrieved from http://irlssg.org/diagnosticcriteria/
13. Kurlan, R., Richard, I. H., & Deeley, C. (2006). Medication tolerance and augmentation in restless legs syndrome: The need for drug class rotation. Journal of General Internal Medicine, 21(12), C1-C4.
14. Kushida, C. A. (2006). Ropinirole for the treatment of resless legs syndrome. Neuropsychiatric Disease and Treatment, 2(4), 407-419.
15. Kushida, C. A., Walters, A. S., Becker P., Thein, S. G., Perkins, A. T., Roth, T., ⋯ Barrett, R. W.; XP021 Study Group. (2009). A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep, 32(2), 159-168.
16. Lee, D. O., Ziman, R. B., Perkins, A. T., Poceta, J. S., Walters, A. S., Barrett, R. W.; XP053 Study Group. (2011). A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. Journal of Clinical Sleep Medicine, 7(3), 282-291.
17. Lipford, M. C., & Silber, M. H. (2012). Long term use of pramipexole in the management of restless legs syndrome. Sleep Medicine, 13(10), 1280-1285.
18. Nagandla, K., & De, S. (2013). Restless legs syndrome: Pathophysiology and modern management. Postgraduate Medical Journal, 89, 402-410.
19. Oertel, W., Trenkwalder, C., Benes, H., Ferini-Strambi, L., Högl, B., & Poewe, W. (2011). Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: A 5-year open-label extension study. The Lancet Neurology, 10(8), 710-720.
20. Parker, K. P., & Rye, D. B. (2002). Restless legs syndrome and periodic limb movement disorder. Nursing Clinics of North America, 37, 655-673.
21. Porcher, E., Remillard, S., & Cohen, H. (2010). Compulsive habits in restless legs syndrome patients under dopaminergic treatment. Journal of the Neurological Sciences, 290(1), 52-56.
22. Sethi, K. D., & Mehta, S. H. (2012). A clinical primer on restless legs syndrome: What we know, and what we don't know. American Journal of Managed Care, 18, 83-88.
23. Thorpy, M. J. (2007). Sleep medicine in primary care: Restless legs syndrome and periodic limb movements. Totowa, NJ: Humana Press.
24. Trenkwalder, C., Benes, H., Poewe, W., Oertel, W., Garcia- Borreguero, D., de Weerd, A. W., ⋯ Kohnen, R.; SP790 Study Group. (2008). Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: A randomized, double-blind, placebo controlled trial. Lancet Neurology, 7, 595-604.
25. UCB. (2013). Neupro (rotigotine transdermal system): Full prescribing information. Smyrna, GA: Author.
26. Walters, A. S. (2003). Validation of the international restless legs syndrome group rating scale for restless legs syndrome. Sleep Medicine, 4, 121-132.
27. Weintraub, D., & Nirenberg, M. J. (2013). Impulse control and related disorders in Parkinson's disease. Neurodegenerative Diseases, 11(2), 63-71.
28. Winkelmann, J., Czamara, D., Schomair, B., Knauf, F., Schulte, E., & Trenkwalder, C. (2011). Genome wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genetics, 7, 2-10.
29. Xenoport. (2013). Horizant (gabapentin enacarbil): Full prescribing information. Santa Clara, CA: Author.